Since PIK3CA mutations are present in multiple types of cancer, the reliable detection of these hotspot mutations is a highly important tool to guide treatment, especially since alpelicib is widely used in the treatment of ER+/HER2- metastatic breast cancer (18). Here, ERBB2 is linked to cancer.